Edition:
United States

argenx NV (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

20.44EUR
17 Nov 2017
Change (% chg)

€-0.02 (-0.10%)
Prev Close
€20.46
Open
€20.70
Day's High
€20.70
Day's Low
€20.29
Volume
6,496
Avg. Vol
10,618
52-wk High
€22.30
52-wk Low
€13.25

Latest Key Developments (Source: Significant Developments)

Argenx launches phase I trial with subcutaneous formulation of ARGX-113​
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - ARGENX NV ::‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​.‍PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS​.‍TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018.‍INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018.​.  Full Article

Argenx 9M total comprehensive loss widens to 16.5 million euros
Thursday, 26 Oct 2017 01:00am EDT 

Oct 26 (Reuters) - ARGENX NV ::REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.9M TOTAL OPERATING INCOME EUR ‍​30.5 MILLION VERSUS EUR 12.5 MILLION YEAR AGO.9M TOTAL COMPREHENSIVE LOSS OF €16.5 MILLION (SEPTEMBER 30, 2016: LOSS €12.6 MILLION).‍​.AS OF SEPT 30 CASH POSITION OF €161.7 MILLION‍​.  Full Article

ArgenX cash and cash equivalents at end H1 stood at 173.4 million euros
Thursday, 24 Aug 2017 01:00am EDT 

Aug 24 (Reuters) - ARGENX NV ::H1 LOSS BEFORE TAXES EUR 7.6 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO.H1 OPERATING LOSS EUR 6.8 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO.H1 REVENUE EUR 22.4 MILLION VERSUS EUR 5.7 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT END H1 EUR 173.4 MILLION VERSUS EUR 108.7 MILLION YEAR AGO.  Full Article

Argenx receives 2nd preclinical milestone payment in Leo Pharma collaboration
Tuesday, 20 Jun 2017 01:00am EDT 

June 20 (Reuters) - ARGENX NV :REG-ARGENX RECEIVES SECOND PRECLINICAL MILESTONE PAYMENT IN COLLABORATION WITH LEO PHARMA.  Full Article

Argenx announces full exercise to purchase additional adss
Friday, 19 May 2017 09:00am EDT 

May 19 (Reuters) - ARGENX NV :ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS.OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM OFFERING TO APPROXIMATELY $114.7 MILLION.  Full Article

Argenx NV's U.S.-listed ADSs open at $17.90 in debut vs IPO price of $17.00/ads
Thursday, 18 May 2017 10:45am EDT 

May 18 (Reuters) - :Argenx NV's U.S.-listed American Depository Shares open at $17.90 in debut on the NASDAQ versus IPO price of $17.00 per ADS.  Full Article

Argenx NV raises about $100 mln gross proceeds with Nasdaq IPO
Wednesday, 17 May 2017 09:57pm EDT 

May 17 (Reuters) - Argenx Nv :Says raises about $100 million gross proceeds with Nasdaq IPO.Says sale of 5,865,000 American Depository shares at a price to public of $17.00 per ADS.  Full Article

Argenx announces size of IPO in US increased to 5 million ADSs
Tuesday, 16 May 2017 01:00am EDT 

May 16 (Reuters) - ARGENX NV ::ARGENX ANNOUNCES SIZE OF INITIAL PUBLIC OFFERING IN THE UNITED STATES INCREASED TO 5 MILLION ADSS.  Full Article

Argenx sees U.S IPO of 3,600,000 american depositary shares
Monday, 8 May 2017 06:22am EDT 

May 8 (Reuters) - Argenx Nv : :Argenx sees U.S IPO of 3,600,000 american depositary shares .  Full Article

Argenx announces launch of proposed initial public offering in the United States
Monday, 8 May 2017 01:01am EDT 

May 8 (Reuters) - ARGENX NV : :ANNOUNCES LAUNCH OF PROPOSED INITIAL PUBLIC OFFERING IN THE UNITED STATES.INTENDS TO OFFER AND SELL 3.6 MILLION AMERICAN DEPOSITARY SHARES ("ADSS") REPRESENTING 3.6 MILLION ORDINARY SHARES IN AN INITIAL PUBLIC OFFERING IN UNITED STATES.  Full Article

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​